Rezolute Inc (RZLT) Stock Price, Quote & News

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 206 4507

Website: www.rezolutebio.com

Address:

275 Shoreline Drive, Suite 500, Redwood City, United States

Curbilicius888 Aug. 31 at 12:36 PM

$INO $RZLT $BFRI Interesting 🤔

0 · Reply

Monty3030 Aug. 31 at 12:02 PM

$RZLT 14.36 Days to Cover 25.73% Short Interest

0 · Reply

KONGLIVES1 Aug. 28 at 7:45 PM

$RZLT

0 · Reply

AnomalyDetective Aug. 28 at 12:40 PM

💥 New Week 36 MDA breakout picks released to members, with Week 35 MDA picks extending the count to 379 weeks with at least one pick gaining over 10% in less than a week: https://seekingalpha.com/mp/1201-value-momentum-breakouts 💥 $GAU on track to be the second pick of the week gaining over 10% and up +28.1% on the live buy signal. 💥 January Piotroski-Graham value portfolio up +28.2% YTD and up +635.7% from 2018 led by $NBR +77.3% YTD 💥 January CFO Insider Trading portfolio up +17.7% YTD vs S&P 500 up +13.5% YTD led by $RZLT +107.6%

0 · Reply

oaksapollo Aug. 28 at 12:15 AM

$RZLT Wish something would happen here. We need to hear that FDA is open to a BLA for cHI based on existing data, and then we need to hear that enrollment is complete in the tumor HI study. These two things happen, and I think we're north of $7.50. With positive tumor HI phase 3, $10+.

1 · Reply

EDP554 Aug. 27 at 10:00 AM

$RZLT those analyst targets don't mean a lot to me. 10 bucks at least.

0 · Reply

Monty3030 Aug. 25 at 2:29 PM

$RZLT Check out this article from TipRanks | Rezolute: Buy Rating Reaffirmed as FDA Catalysts Support CGM‑Driven Upside, Price Target Maintained at $6 | https://tipranks.onelink.me/WJho/267tbenz Expecting news next month!!

0 · Reply

KONGLIVES1 Aug. 25 at 10:55 AM

$RZLT stock is showing some signs of life in volume . I think people are realizing big news is coming either way . Good luck enjoy the ride.

0 · Reply

Monty3030 Aug. 25 at 10:48 AM

$RZLT 7.54 Days to Cover 25.73% Short Interest

0 · Reply

KONGLIVES1 Aug. 24 at 6:53 PM

$RZLT RZLV anyone input ?

0 · Reply

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jun 26, 2026, 7:00 AM EDT - 2 months ago

Rezolute Slides: Corporate presentation

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

2026-06-15T10:41:18.000Z - 2 months ago

Rezolute price target raised to $11, named a Best Idea at Guggenheim

Jun 4, 2026, 3:45 PM EDT - 3 months ago

Rezolute Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 3:45 PM EDT - 3 months ago

Rezolute Slides: FY 2026

Jun 4, 2026, 7:30 AM EDT - 3 months ago

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

2026-06-03T15:04:08.000Z - 3 months ago

Rezolute price target raised to $14 from $10 at Maxim

2026-06-03T12:16:54.000Z - 3 months ago

Rezolute price target raised to $6 from $5 at Wedbush

2026-06-03T08:36:37.000Z - 3 months ago

Rezolute upgraded to Outperform from Market Perform at Citizens

2026-06-02T19:55:11.000Z - 3 months ago

Rezolute price target raised to $6 from $5 at BTIG

2026-06-02T19:00:14.000Z - 3 months ago

Rezolute price target raised to $14 from $10 at Maxim

2026-06-02T11:31:37.000Z - 3 months ago

Rezolute provides interim update on ersodetug study

Jun 2, 2026, 7:00 AM EDT - 3 months ago

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

2026-05-14T14:28:58.000Z - 3 months ago

Rezolute price target raised to $10 from $4 at Maxim

2026-05-12T21:34:01.000Z - 3 months ago

Rezolute reports Q3 EPS (16c), consensus (17c)

May 12, 2026, 4:05 PM EDT - 3 months ago

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 12, 2026, 4:00 PM EDT - 3 months ago

Rezolute Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Rezolute Quarterly report: Q3 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Rezolute to Participate in Upcoming Investor Conferences

May 7, 2026, 7:00 AM EDT - 4 months ago

Rezolute Slides: Corporate presentation

2026-05-01T16:21:30.000Z - 4 months ago

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

May 1, 2026, 12:15 PM EDT - 4 months ago

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Apr 24, 2026, 9:00 AM EDT - 4 months ago

Rezolute, Inc. Investigated by the Portnoy Law Firm

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Rezolute Slides: Corporate presentation

2026-03-25T10:46:08.000Z - 5 months ago

Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI

2026-03-25T10:37:36.000Z - 5 months ago

Rezolute upgraded to Outperform from Neutral at Wedbush

2026-03-24T11:26:35.000Z - 5 months ago

Rezolute provides update on sunRIZE study following Type B meeting with FDA

Mar 24, 2026, 7:00 AM EDT - 5 months ago

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Mar 4, 2026, 7:00 AM EST - 6 months ago

Rezolute to Participate in the Citizens Life Sciences Conference

2026-03-03T14:56:44.000Z - 6 months ago

Rezolute management to meet with Maxim

2026-02-12T21:16:42.000Z - 7 months ago

Rezolute reports Q2 EPS (22c), consensus (18c)

Feb 12, 2026, 4:05 PM EST - 7 months ago

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 12, 2026, 4:00 PM EST - 7 months ago

Rezolute Quarterly report: Q2 2026

Feb 12, 2026, 4:00 PM EST - 7 months ago

Rezolute Earnings release: Q2 2026

Feb 4, 2026, 7:00 AM EST - 7 months ago

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-08T13:05:22.000Z - 8 months ago

Rezolute price target raised to $2 from $1 at Wedbush

2026-01-07T12:17:20.000Z - 8 months ago

Rezolute shares findings from Expanded Access Program in tumor HI

2026-01-07T12:10:43.000Z - 8 months ago

Rezolute shares observations from Phase 3 sunRIZE study in congenital HI

Jan 7, 2026, 7:00 AM EST - 8 months ago

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Jan 7, 2026, 7:00 AM EST - 8 months ago

Rezolute Slides: Corporate Presentation

Dec 11, 2025, 2:39 PM EST - 9 months ago

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Dec 11, 2025, 8:30 AM EST - 9 months ago

Rezolute Transcript: Study Result

Dec 11, 2025, 8:30 AM EST - 9 months ago

Rezolute Press release: Study Result

Dec 11, 2025, 7:05 AM EST - 9 months ago

Rezolute's rare disease drug fails main goal in late-stage trial

Dec 11, 2025, 7:00 AM EST - 9 months ago

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Nov 19, 2025, 6:00 PM EST - 10 months ago

Rezolute Transcript: AGM 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Rezolute Slides: Corporate Presentation

Nov 10, 2025, 5:30 PM EST - 10 months ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 12:00 PM EST - 10 months ago

Rezolute Transcript: Status Update

Nov 6, 2025, 4:05 PM EST - 10 months ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:00 PM EST - 10 months ago

Rezolute Quarterly report: Q1 2026

Nov 6, 2025, 4:00 PM EST - 10 months ago

Rezolute Earnings release: Q1 2026

Nov 5, 2025, 7:30 AM EST - 10 months ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Rezolute Proxy statement: Proxy Filing

Sep 17, 2025, 4:05 PM EDT - 1 year ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Curbilicius888 Aug. 31 at 12:36 PM

$INO $RZLT $BFRI Interesting 🤔

0 · Reply

Monty3030 Aug. 31 at 12:02 PM

$RZLT 14.36 Days to Cover 25.73% Short Interest

0 · Reply

KONGLIVES1 Aug. 28 at 7:45 PM

$RZLT

0 · Reply

AnomalyDetective Aug. 28 at 12:40 PM

0 · Reply

oaksapollo Aug. 28 at 12:15 AM

1 · Reply

EDP554 Aug. 27 at 10:00 AM

$RZLT those analyst targets don't mean a lot to me. 10 bucks at least.

0 · Reply

Monty3030 Aug. 25 at 2:29 PM

0 · Reply

KONGLIVES1 Aug. 25 at 10:55 AM

$RZLT stock is showing some signs of life in volume . I think people are realizing big news is coming either way . Good luck enjoy the ride.

0 · Reply

Monty3030 Aug. 25 at 10:48 AM

$RZLT 7.54 Days to Cover 25.73% Short Interest

0 · Reply

KONGLIVES1 Aug. 24 at 6:53 PM

$RZLT RZLV anyone input ?

0 · Reply

Monty3030 Aug. 22 at 1:32 AM

$RZLT 23.36 Days to Cover 25.73% Short Interest

0 · Reply

LSOTradingDesk Aug. 21 at 7:42 PM

$RZLT well this is a nice surprise, wasn't expecting much this morning.

0 · Reply

KONGLIVES1 Aug. 21 at 4:36 PM

$RZLT what’s up? I can find no news.

0 · Reply

ajmrtxl Aug. 21 at 2:16 PM

$RZLT 's latest squeeze play

1 · Reply

oaksapollo Aug. 21 at 2:13 PM

$RZLT

0 · Reply

Monty3030 Aug. 21 at 2:06 PM

$RZLT Let's break $5.42!!!

1 · Reply

KONGLIVES1 Aug. 21 at 1:03 PM

$RZLT rzlv any thoughts

0 · Reply

oaksapollo Aug. 18 at 1:51 PM

$RZLT potential threat to ersodetug down the road https://www.biopharmadive.com/news/amylyx-glp1-avexitide-clinical-trial-results-blood-sugar/828099/

0 · Reply

KONGLIVES1 Aug. 18 at 1:26 AM

$RZLT Bank Of Mellon sold 500,000 shares or 71” percent of their shares

0 · Reply

KONGLIVES1 Aug. 17 at 3:43 PM

$RZLT volume volume volume double edge sword . That should be the tell

0 · Reply

Monty3030 Aug. 17 at 12:32 PM

$RZLT 23.87 Days to Cover 26.81% Short Interest

0 · Reply

Marketman707 Aug. 15 at 12:19 AM

$RZLT I do believe in the company, this is just an unfortunate result. Will be watching and wishing for a good time to enter

0 · Reply

Market Cap	444.87M
Revenue (ttm)	0.00
Net Income (ttm)	-74.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	749,000
Avg Vol	1,651,942
Day's Range	N/A - N/A
Shares Out	96.29M
Stochastic %K	10%
Beta	0.58
Analysts	Strong Sell
Price Target	$7.67